Management of early and late toxicities of autologous hematopoietic stem cell transplantation

Sai Ravi Pingali; Yago Nieto

doi:10.1002/9781118863282.ch10

Management of early and late toxicities of autologous hematopoietic stem cell transplantation

Research output: Chapter in Book/Report/Conference proceeding › Chapter

Abstract

Autologous stem cell transplantation (ASCT) is an effective treatment option for various lymphoid malignancies. ASCT allows delivery of high-dose chemotherapy (HDC) without concerns for hematologic toxicities, and in certain settings is superior to conventional chemotherapy alone. Although recurrent disease is the most common cause of mortality in ASCT recipients, early and late side effects account for 31% of deaths. Toxicities from ASCT depend on the disease, HDC regimen, previous therapies, age, performance status, and comorbidities. In this chapter we discuss early and late toxic effects of ASCT and their management.

Original language	English (US)
Title of host publication	Clinical Guide to Transplantation in Lymphoma
Publisher	Wiley
Pages	93-102
Number of pages	10
ISBN (Electronic)	9781118863282
ISBN (Print)	9781118863329
DOIs	https://doi.org/10.1002/9781118863282.ch10
State	Published - Jan 1 2015

Keywords

early
late
toxicities of autologous transplantation

ASJC Scopus subject areas

General Medicine

Access to Document

10.1002/9781118863282.ch10

Cite this

@inbook{b274858cadbc4b4b949f2c161aabc73a,

title = "Management of early and late toxicities of autologous hematopoietic stem cell transplantation",

abstract = "Autologous stem cell transplantation (ASCT) is an effective treatment option for various lymphoid malignancies. ASCT allows delivery of high-dose chemotherapy (HDC) without concerns for hematologic toxicities, and in certain settings is superior to conventional chemotherapy alone. Although recurrent disease is the most common cause of mortality in ASCT recipients, early and late side effects account for 31% of deaths. Toxicities from ASCT depend on the disease, HDC regimen, previous therapies, age, performance status, and comorbidities. In this chapter we discuss early and late toxic effects of ASCT and their management.",

keywords = "early, late, toxicities of autologous transplantation",

author = "Pingali, {Sai Ravi} and Yago Nieto",

note = "Publisher Copyright: {\textcopyright} 2015 by John Wiley & Sons, Ltd.",

year = "2015",

month = jan,

day = "1",

doi = "10.1002/9781118863282.ch10",

language = "English (US)",

isbn = "9781118863329",

pages = "93--102",

booktitle = "Clinical Guide to Transplantation in Lymphoma",

publisher = "Wiley",

address = "United Kingdom",

}

TY - CHAP

T1 - Management of early and late toxicities of autologous hematopoietic stem cell transplantation

AU - Pingali, Sai Ravi

AU - Nieto, Yago

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Autologous stem cell transplantation (ASCT) is an effective treatment option for various lymphoid malignancies. ASCT allows delivery of high-dose chemotherapy (HDC) without concerns for hematologic toxicities, and in certain settings is superior to conventional chemotherapy alone. Although recurrent disease is the most common cause of mortality in ASCT recipients, early and late side effects account for 31% of deaths. Toxicities from ASCT depend on the disease, HDC regimen, previous therapies, age, performance status, and comorbidities. In this chapter we discuss early and late toxic effects of ASCT and their management.

AB - Autologous stem cell transplantation (ASCT) is an effective treatment option for various lymphoid malignancies. ASCT allows delivery of high-dose chemotherapy (HDC) without concerns for hematologic toxicities, and in certain settings is superior to conventional chemotherapy alone. Although recurrent disease is the most common cause of mortality in ASCT recipients, early and late side effects account for 31% of deaths. Toxicities from ASCT depend on the disease, HDC regimen, previous therapies, age, performance status, and comorbidities. In this chapter we discuss early and late toxic effects of ASCT and their management.

KW - early

KW - late

KW - toxicities of autologous transplantation

UR - http://www.scopus.com/inward/record.url?scp=86000688083&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=86000688083&partnerID=8YFLogxK

U2 - 10.1002/9781118863282.ch10

DO - 10.1002/9781118863282.ch10

M3 - Chapter

AN - SCOPUS:86000688083

SN - 9781118863329

SP - 93

EP - 102

BT - Clinical Guide to Transplantation in Lymphoma

PB - Wiley

ER -

Management of early and late toxicities of autologous hematopoietic stem cell transplantation

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this